AngioDynamics (ANGO) Reports In-Line Q2 EPS; Trims FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
AngioDynamics (ANGO) PT Cut at Piper Jaffray
January 8, 2016 7:34 AM ESTAngioDynamics (NASDAQ: ANGO) met expectations for its Q2 (Nov) revenues and earnings, but cut guidance for the remainder of the year as the vascular access business has been adjusting to a Q3 recall from last year. Piper Jaffray analyst, Thomas Gunderson, lowered numbers as a result.
The Morpheus product was taken off the market, and the sales force diverted effort to try to retain customers. Not only was retention more... More
